1.64Open1.64Pre Close0 Volume1 Open Interest22.50Strike Price0.00Turnover392.27%IV27.97%PremiumSep 20, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry1.64Extrinsic Value100Contract SizeAmericanOptions Type-0.2035Delta0.0242Gamma17.66Leverage Ratio-0.4467Theta-0.0008Rho-3.59Eff Leverage0.0084Vega
Spyre Therapeutics Stock Discussion
U.S. stocks advanced on Monday, building off a record finish ahead of the ramping up of fourth-quarter earnings season.
The $Dow Jones Industrial Average (.DJI.US)$ rose 138 points, or 0.26%, to 38,000. The $S&P 500 Index (.SPX.US)$ was up 10 points, or 0.22%, at 4,850. The $Nasdaq Composite Index (.IXIC.US)$advanced 49 points, or 0.32%, to 15,360.
While the S&P 500 finally returned to record territory on Friday, skeptic...
Spyre felt the positive pressure from fresh buy ratings by analysts like Stifel. $Ginkgo Bioworks (DNA.US)$ also roase 9%, despite a new sell rating from Goldman Sachs.
But monday morning was not al...
No comment yet